Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

8.380 -0.360 (-4.12%)
Streaming Delayed Price Updated: 12:35 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvectis Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung... 
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
Event scheduled for Tuesday, December 2nd at 8:00 AM ET 
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis (NVCT) Q2 Loss Widens 43% ↗
Via The Motley Fool
News headline image
Discover the top movers in Thursday's pre-market session. ↗
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
With clinical catalysts on the horizon and a seasoned biotech insider doubling down, Could Nuvectis Pharma (NASDAQ:NVCT)* Become the Next Summit Therapeutics (NASDAQ: SMMT)? 
Via News Direct
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma's NXP900: Could This Revolutionary Cancer "Inactivator" Transform Oncology Treatment?
Truffle Pigs Blog Highlights Potential Game-Changing Cancer Therapy with Unique Mechanism of Action 
Via News Direct
News headline image
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
From Market News Alerts
Via Business Wire
News headline image
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
Research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) 
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
From Market News Alerts
Via Business Wire
News headline image
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug ↗
Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing. 
Via Benzinga
News headline image
S&P 500 Moves Lower; US Crude Oil Inventories Increase ↗
 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.